It has been suggested that EGFR-TKIs or PD-1/PD-L1 inhibitors may also play a therapeutic role in NSCLC through anti-inflammatory and antioxidant mechanisms (Liao et al., 2012). This evidence concerns the gene CD274 and non-small cell lung carcinoma.